Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Study ID
- NCT06582615
- Status
- Recruiting
Conditions
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 40 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Biospecimen Collection — PROCEDUREUndergo dried blood spot collection
- Cognitive Assessment — PROCEDUREAncillary studies
- Dietary Intervention — OTHERReceive MIND counseling sessions
- Dietary Intervention — OTHERFollow a personalized diet
- Dietary Intervention — OTHERReceive general health recommendations counseling sessions
- Medical Device Usage and Evaluation — OTHERWear a Fitbit
- Questionnaire Administration — OTHERAncillary studies
Study Details
The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other symptoms commonly experienced by women with newly diagnosed stage II-III triple negative breast cancer as they go through chemotherapy. The symptoms that will be measured include changes in memory and mental function, fatigue, sleep quality, anxiety, and depression. Researchers will compare measures from women in the 12-week MIND eating plan virtual intervention to a general health coaching (GHC) virtual intervention to see if the MIND eating plan helps reduce symptoms. Women will be contacted for follow-up measures 6 months after the 12-week interventions. Women randomly assigned to the GHC at the beginning of the study will have the opportunity to complete the MIND intervention after the 6-month follow-up. All study sessions and measures are done remotely. Participants will: * Be randomized to MIND or GHC interventions * Complete all study measures remotely (by online questionnaires, virtual visits and mail ) * Attend 8 virtual sessions of about 15-60 minutes each over 12 weeks * Be sent some of the key foods in the MIND eating plan during the MIND intervention * Be contacted for follow-up measures 6 months after interventions
Key Dates
- Start date
- Oct 28, 2024
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Arm I (MIND-TNBC counseling)Patients receive MIND counseling sessions over 30-60 minutes weekly for 4 weeks then over 15 minutes biweekly for 4 sessions over 8 weeks and follow a personalized diet for 12 weeks. Patients also wear a Fitbit and undergo dried blood spot collection on study and during follow up.
- Active Comparator: Arm II (general health recommendations counseling)Patients receive general health recommendations counseling sessions over 30-60 minutes weekly for 4 weeks then over 15 minutes biweekly for 4 sessions over 8 weeks. Patients also wear a Fitbit and undergo dried blood spot collection on study and during follow up. After 6 month follow-up, patients may receive the MIND counseling sessions as in Arm I.
Primary Outcome Measure
Changes in Wechsler Adult Intelligence Scale, fourth edition (WAIS-IV) Digit Span score [ Time Frame: Baseline up to 6 months post-intervention ]
Central Contacts
- The Ohio State University Comprehensive Cancer Center800-293-5066
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale University | New Haven | Connecticut | 06519 | |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Tonya Orchard (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New Haven, CT
Related Studies
- Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize TrialPHASE3 · Recruiting · Alliance for Clinical Trials in Oncology · Ann Arbor, Michigan
- Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast CancerEARLY_PHASE1 · Recruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerPHASE1 · Recruiting · National Cancer Institute (NCI) · Boston, Massachusetts
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama